Thus, these gene fusions, specifically TMPRSS2-ERG fusions, could be used as targets for effective prevention/intervention strategies and stratification of homogenous PCa patient populations in drug efficacy trials [36,37]. This evidence concerns the gene TMPRSS2 and posterior cortical atrophy.